NGVT · NYSE
Average $92.48 (+31.0% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Wells Fargo | Feb 27, 2026 | Maintains | Equal-Weight |
| Wells Fargo | Jan 29, 2026 | Maintains | Equal-Weight |
| Wells Fargo | Dec 19, 2025 | Maintains | Equal-Weight |
| BMO Capital | Dec 10, 2025 | Maintains | Outperform |
| Wells Fargo | Nov 12, 2025 | Maintains | Equal-Weight |
Updated Feb 9, 2026
Ingevity Corp demonstrates a positive outlook due to effective management execution aimed at enhancing its portfolio through strategic asset sales, which are expected to reduce earnings volatility. The focus on refining operations is anticipated to bolster the company's margin profile significantly. Furthermore, the strong performance of the Performance Chemicals segment, which generates the majority of revenue, underpins the financial stability and growth potential of the company.
Ingevity Corp faces significant risks that contribute to a negative outlook, primarily related to the potential decline in global auto production, which could negatively impact the company’s earnings and valuation multiples. The company’s dependency on transitioning its customer base towards automotive focused applications adds an additional layer of uncertainty, especially if it cannot adapt effectively and timely. Furthermore, various operational risks, including patent expirations, tariff impacts on the Performance Materials segment, weather-related disruptions, and competitive pressures, further complicate its financial stability and outlook.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
